Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(553 productos)
- FAK(72 productos)
- FLT(86 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(176 productos)
- JAK(244 productos)
- PDGFR(127 productos)
- RAAS(85 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(55 productos)
- VDA(2 productos)
- VEGFR(237 productos)
Mostrar 6 subcategorías más
Se han encontrado 2300 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Grb2 SH2 domain inhibitor 1
Grb2 SH2 Domain Inhibitor 1 is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where ΦForma y color:Odour SolidLDN 193688
CAS:LDN 193688 is a BMP kinase inhibitor preferential for the ALK2 site, acting by binding to the ALK site,progressive osseous fibrodysplasia.Fórmula:C22H16N4OPureza:99.48%Forma y color:SoildPeso molecular:352.39EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Fórmula:C25H18N4O3Pureza:98%Forma y color:SolidPeso molecular:422.44Anti-FLT3 Antibody (AGS62P)
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3 for research in acute myeloid leukemia.Forma y color:Odour LiquidALK-IN-13
CAS:ALK-IN-13 is an ALK inhibitor.
Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1FAK-IN-27
FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).Fórmula:C32H28ClN5O6Forma y color:SolidPeso molecular:613.17281Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77CPD-1224
CAS:CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Fórmula:C43H47ClN8O7SForma y color:SolidPeso molecular:855.4FLT3-IN-10
CAS:FLT3-IN-10, a potent FLT3 inhibitor, may treat FLT3-mutated AML.Fórmula:C15H11FN2OPureza:99.8%Forma y color:SolidPeso molecular:254.26Ref: TM-T9856
2mg38,00€5mg59,00€10mg92,00€25mg182,00€50mg268,00€100mg380,00€200mg517,00€1mL*10mM (DMSO)57,00€Ifebemtinib hydrochloride
Ifebemtinib (BI-853520) hydrochloride is a potent FAK (focal adhesion kinase) inhibitor with oral bioavailability, exhibiting an IC50 of 1 nM for recombinant FAK. Ifebemtinib hydrochloride demonstrates antiproliferative activity against cancer cells.Fórmula:C28H29ClF4N6O4Forma y color:SolidPeso molecular:625.01HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Forma y color:Odour SolidDD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163FGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Fórmula:C26H27N4O6PPureza:98%Forma y color:SolidPeso molecular:522.49FAK-IN-11
FAK-IN-11 (Compound 4l), a FAK inhibitor, specifically targets the ATP binding pocket of FAK to prevent its phosphorylation.Fórmula:C25H41NO3Pureza:98%Forma y color:SolidPeso molecular:403.6BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Fórmula:C26H23N7OPureza:98%Forma y color:SolidPeso molecular:449.51EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Fórmula:C27H31N3O2Forma y color:SolidPeso molecular:429.24163AG01
AG01 is a monoclonal antibody targeting the anti-granular protein precursor (GP88). It inhibits the proliferation and migration of triple-negative breast cancer (TNBC) cells, reducing the expression of phosphorylated protein kinases such as p-Src, p-AKT, and p-ERK, as well as oncogenic proteins like Axl, c-MET, HIF-1α, and VEGF. In TNBC xenograft mouse models, AG01 suppresses tumor growth and the expression of Ki67 in vivo. AG01 is useful for research involving cancers like TNBC.Forma y color:Odour LiquidPROTAC BTK Degrader-11
CAS:PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Fórmula:C48H55N11O4Forma y color:SolidPeso molecular:850.02KLTWQELYQLKYKGI
CAS:KLTWQELYQLKYKGI (QK) is a VEGF-mimicking peptide that competes with VEGF by binding to its receptors.Fórmula:C92H143N21O23Pureza:98%Forma y color:SolidPeso molecular:1911.25
